Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 10 , Pages 1105-1113, October 2008

Psychopharmacological Treatment Options for Global Child and Adolescent Mental Health: The WHO Essential Medicines Lists

All of the authors are with the Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada

Accepted 10 April 2008.

Disclosure: Drs. Murphy, Gardner, and Kutcher co-developed Med Ed © 2008, an information resource and communications tool for youths with mental illnesses taking psychotropic medications and their caregivers. This project was supported by a contract from the Provincial Centre of Excellence for Child and Youth Mental Health at the Children's Hospital of Eastern Ontario. None of the authors has received royalties from this tool. Dr. Murphy receives salary support from the Sun Life Financial Chair in Adolescent Mental Health for her position as a research associate. She is the principal investigator of a research grant that is examining antipsychotic drug use in Nova Scotia's children and adolescents. The research is funded by the Nova Scotia Health Research Foundation (2007–2010). Dr. Gardner is the co-principal investigator on this project and Dr. Kutcher is a co-investigator. Dr. Gardner has received honoraria as a speaker and participant at meetings sponsored by AstraZeneca, Pfizer, Eli Lilly, and Janssen. Dr. Kutcher has been a consultant to the Lundbeck Institute.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Psychopharmacology Perspectives aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The discussions may address aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with often complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of the thought process that may go into pharmacotherapy decision making.

PII: S0890-8567(08)60094-5

doi:10.1097/CHI.0b013e3181825ae1

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 10 , Pages 1105-1113, October 2008

Article Tools